153 related articles for article (PubMed ID: 33824127)
21. Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease.
Chen J; Farraj RA; Limonta D; Tabatabaei Dakhili SA; Kerek EM; Bhattacharya A; Reformat FM; Mabrouk OM; Brigant B; Pfeifer TA; McDermott MT; Ussher JR; Hobman TC; Glover JNM; Hubbard BP
J Biol Chem; 2023 Nov; 299(11):105341. PubMed ID: 37832873
[TBL] [Abstract][Full Text] [Related]
22. Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants.
Wilson IM; Frazier MN; Li JL; Randall TA; Stanley RE
J Mol Biol; 2022 Oct; 434(20):167796. PubMed ID: 35995266
[TBL] [Abstract][Full Text] [Related]
23. Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.
Hong S; Seo SH; Woo SJ; Kwon Y; Song M; Ha NC
J Agric Food Chem; 2021 Jun; 69(21):5948-5954. PubMed ID: 34015930
[TBL] [Abstract][Full Text] [Related]
24. Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19.
Barros RO; Junior FLCC; Pereira WS; Oliveira NMN; Ramos RM
J Proteome Res; 2020 Nov; 19(11):4567-4575. PubMed ID: 32786890
[TBL] [Abstract][Full Text] [Related]
25. The Efficacious Benefit of 25-Hydroxy Vitamin D to Prevent COVID-19: An In-Silico Study Targeting SARS-CoV-2 Spike Protein.
Joseph TM; Suresh AM; Kar Mahapatra D; Haponiuk J; Thomas S
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500994
[TBL] [Abstract][Full Text] [Related]
26. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
Chandra A; Gurjar V; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
[TBL] [Abstract][Full Text] [Related]
27. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an
Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK
J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934
[TBL] [Abstract][Full Text] [Related]
28. Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease.
Stevaert A; Krasniqi B; Van Loy B; Nguyen T; Thomas J; Vandeput J; Jochmans D; Thiel V; Dijkman R; Dehaen W; Voet A; Naesens L
J Med Chem; 2021 May; 64(9):5632-5644. PubMed ID: 33877845
[TBL] [Abstract][Full Text] [Related]
29. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
30. Structure-based drug designing towards the identification of potential anti-viral for COVID-19 by targeting endoribonuclease NSP15.
Krishnan DA; Sangeetha G; Vajravijayan S; Nandhagopal N; Gunasekaran K
Inform Med Unlocked; 2020; 20():100392. PubMed ID: 32835078
[TBL] [Abstract][Full Text] [Related]
31. Flipped over U: structural basis for dsRNA cleavage by the SARS-CoV-2 endoribonuclease.
Frazier MN; Wilson IM; Krahn JM; Butay KJ; Dillard LB; Borgnia MJ; Stanley RE
Nucleic Acids Res; 2022 Aug; 50(14):8290-8301. PubMed ID: 35801916
[TBL] [Abstract][Full Text] [Related]
32. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein.
Bhardwaj K; Liu P; Leibowitz JL; Kao CC
J Virol; 2012 Apr; 86(8):4294-304. PubMed ID: 22301153
[TBL] [Abstract][Full Text] [Related]
33. Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U.
Frazier MN; Dillard LB; Krahn JM; Perera L; Williams JG; Wilson IM; Stewart ZD; Pillon MC; Deterding LJ; Borgnia MJ; Stanley RE
Nucleic Acids Res; 2021 Sep; 49(17):10136-10149. PubMed ID: 34403466
[TBL] [Abstract][Full Text] [Related]
34. In Situ Tagged nsp15 Reveals Interactions with Coronavirus Replication/Transcription Complex-Associated Proteins.
Athmer J; Fehr AR; Grunewald M; Smith EC; Denison MR; Perlman S
mBio; 2017 Jan; 8(1):. PubMed ID: 28143984
[TBL] [Abstract][Full Text] [Related]
35. Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an
Mahmud S; Elfiky AA; Amin A; Mohanto SC; Rahman E; Acharjee UK; Saleh A
Future Virol; 2021 Jun; ():. PubMed ID: 34290822
[TBL] [Abstract][Full Text] [Related]
36. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
37. Antibiotic-Induced Primary Biles Inhibit SARS-CoV-2 Endoribonuclease Nsp15 Activity in Mouse Gut.
Ma Y; Luo M; Deng Y; Yang X; Wang X; Chen G; Qin Z; Deng Y; Nan M; Chen Y; Wang P; Wei H; Han L; Fang X; Liu Z
Front Cell Infect Microbiol; 2022; 12():896504. PubMed ID: 35967852
[TBL] [Abstract][Full Text] [Related]
38. Identification of bioactive compounds from
Sinha SK; Prasad SK; Islam MA; Gurav SS; Patil RB; AlFaris NA; Aldayel TS; AlKehayez NM; Wabaidur SM; Shakya A
J Biomol Struct Dyn; 2021 Aug; 39(13):4686-4700. PubMed ID: 32552462
[TBL] [Abstract][Full Text] [Related]
39. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
40. Structure-guided pharmacophore based virtual screening, docking, and molecular dynamics to discover repurposed drugs as novel inhibitors against endoribonuclease Nsp15 of SARS-CoV-2.
Jha P; Saluja D; Chopra M
J Biomol Struct Dyn; 2023 Jul; 41(11):5096-5106. PubMed ID: 35652904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
